Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32880196)

  • 1. Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer.
    Rimel BJ; Dockery L; Randall LM; Moore K
    Future Oncol; 2020 Nov; 16(33):2701-2711. PubMed ID: 32880196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
    Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
    Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niraparib: First Global Approval.
    Scott LJ
    Drugs; 2017 Jun; 77(9):1029-1034. PubMed ID: 28474297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niraparib: A Review in Ovarian Cancer.
    Heo YA; Duggan ST
    Target Oncol; 2018 Aug; 13(4):533-539. PubMed ID: 30073633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
    Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
    Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.
    Gonzalez Martin A; Sanchez Lorenzo L; Colombo N; dePont Christensen R; Heitz F; Meirovitz M; Selle F; van Gorp T; Alvarez N; Sanchez J; Marqués C
    Int J Gynecol Cancer; 2021 Apr; 31(4):617-622. PubMed ID: 33318079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China.
    Ni J; Cheng X; Zhao Q; Dai Z; Xu X; Guo W; Gu H; Zhou R; Wang Y; Chen X
    J Ovarian Res; 2021 May; 14(1):68. PubMed ID: 33993885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
    AlHilli MM; Becker MA; Weroha SJ; Flatten KS; Hurley RM; Harrell MI; Oberg AL; Maurer MJ; Hawthorne KM; Hou X; Harrington SC; McKinstry S; Meng XW; Wilcoxen KM; Kalli KR; Swisher EM; Kaufmann SH; Haluska P
    Gynecol Oncol; 2016 Nov; 143(2):379-388. PubMed ID: 27614696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human mass balance study and metabolite profiling of
    van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Lucas L; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH
    Invest New Drugs; 2017 Dec; 35(6):751-765. PubMed ID: 28303528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
    Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R
    Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niraparib for the treatment of ovarian cancer.
    Essel KG; Moore KN
    Expert Rev Anticancer Ther; 2018 Aug; 18(8):727-733. PubMed ID: 29911447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer.
    Longoria TC; Tewari KS
    Expert Opin Drug Metab Toxicol; 2018 May; 14(5):543-550. PubMed ID: 29620474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Niraparib for the treatment of ovarian cancer.
    Kanjanapan Y; Lheureux S; Oza AM
    Expert Opin Pharmacother; 2017 Apr; 18(6):631-640. PubMed ID: 28299955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    González-Martín A; Pothuri B; Vergote I; DePont Christensen R; Graybill W; Mirza MR; McCormick C; Lorusso D; Hoskins P; Freyer G; Baumann K; Jardon K; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Lund B; Backes F; Barretina-Ginesta P; Haggerty AF; Rubio-Pérez MJ; Shahin MS; Mangili G; Bradley WH; Bruchim I; Sun K; Malinowska IA; Li Y; Gupta D; Monk BJ;
    N Engl J Med; 2019 Dec; 381(25):2391-2402. PubMed ID: 31562799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
    Kurnit KC; Coleman RL; Westin SN
    Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niraparib Slows Ovarian Cancer Progression.
    Cancer Discov; 2016 Dec; 6(12):OF2. PubMed ID: 27810860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
    Fabbro M; Moore KN; Dørum A; Tinker AV; Mahner S; Bover I; Banerjee S; Tognon G; Goffin F; Shapira-Frommer R; Wenham RM; Hellman K; Provencher D; Harter P; Vázquez IP; Follana P; Pineda MJ; Mirza MR; Hazard SJ; Matulonis UA
    Gynecol Oncol; 2019 Mar; 152(3):560-567. PubMed ID: 30638768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Moore K; Chan JK; Secord AA; Patel MR; Callahan T; Guo W; Zhang ZY
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):717-726. PubMed ID: 30680521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a
    van Andel L; Rosing H; Zhang Z; Hughes L; Kansra V; Sanghvi M; Tibben MM; Gebretensae A; Schellens JHM; Beijnen JH
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):39-46. PubMed ID: 29043410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
    Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.